Reports - Next-gen Biomanufacturing Market
HealthcareNext-gen Biomanufacturing Market
Next-gen Biomanufacturing Market Growth and Trends | Insights & Forecast 2025-2035 by Workflow Type (Continuous Upstream Biomanufacturing Workflow, Single-Use Upstream Biomanufacturing Workflow, Downstream Biomanufacturing Workflow) by Application (Monoclonal Antibodies, Vaccines, Hormones, Recombinant Proteins, Other Applications) by End User (Biopharmaceutical Companies, Research Institutions, CMOs/CDMOs) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Next-gen Biomanufacturing Market - Segment Analysis
1. Overview
2. Global Next-gen Biomanufacturing Market, 2021 - 2035 (USD Million)
3. Global Next-gen Biomanufacturing Market - by Workflow Type
3.1. By Continuous Upstream Biomanufacturing Workflow
3.2. By Single-Use Upstream Biomanufacturing Workflow
3.3. By Downstream Biomanufacturing Workflow
4. Global Next-gen Biomanufacturing Market - by Application
4.1. By Monoclonal Antibodies
4.2. By Vaccines
4.3. By Hormones
4.4. By Recombinant Proteins
4.5. By Other Applications
5. Global Next-gen Biomanufacturing Market - by End User
5.1. By Biopharmaceutical Companies
5.2. By Research Institutions
5.3. By CMOs/CDMOs
6. Global Next-gen Biomanufacturing Market - by region
6.1. North America
6.2. Europe
6.3. Asia Pacific
6.4. Latin America
6.5. Middle East & Africa
7. Market comparative analysis
Chapter 4 North America Next-gen Biomanufacturing Market - Segment Analysis
1. Overview
2. North America Next-gen Biomanufacturing Market, 2021 - 2035 (USD Million)
3. North America Next-gen Biomanufacturing Market - by Workflow Type
3.1. By Continuous Upstream Biomanufacturing Workflow
3.2. By Single-Use Upstream Biomanufacturing Workflow
3.3. By Downstream Biomanufacturing Workflow
4. North America Next-gen Biomanufacturing Market - by Application
4.1. By Monoclonal Antibodies
4.2. By Vaccines
4.3. By Hormones
4.4. By Recombinant Proteins
4.5. By Other Applications
5. North America Next-gen Biomanufacturing Market - by End User
5.1. By Biopharmaceutical Companies
5.2. By Research Institutions
5.3. By CMOs/CDMOs
Chapter 5 Europe Next-gen Biomanufacturing Market - Segment Analysis
1. Overview
2. Europe Next-gen Biomanufacturing Market, 2021 - 2035 (USD Million)
3. Europe Next-gen Biomanufacturing Market - by Workflow Type
3.1. By Continuous Upstream Biomanufacturing Workflow
3.2. By Single-Use Upstream Biomanufacturing Workflow
3.3. By Downstream Biomanufacturing Workflow
4. Europe Next-gen Biomanufacturing Market - by Application
4.1. By Monoclonal Antibodies
4.2. By Vaccines
4.3. By Hormones
4.4. By Recombinant Proteins
4.5. By Other Applications
5. Europe Next-gen Biomanufacturing Market - by End User
5.1. By Biopharmaceutical Companies
5.2. By Research Institutions
5.3. By CMOs/CDMOs
Chapter 6 Asia Pacific Next-gen Biomanufacturing Market - Segment Analysis
1. Overview
2. Asia Pacific Next-gen Biomanufacturing Market, 2021 - 2035 (USD Million)
3. Asia Pacific Next-gen Biomanufacturing Market - by Workflow Type
3.1. By Continuous Upstream Biomanufacturing Workflow
3.2. By Single-Use Upstream Biomanufacturing Workflow
3.3. By Downstream Biomanufacturing Workflow
4. Asia Pacific Next-gen Biomanufacturing Market - by Application
4.1. By Monoclonal Antibodies
4.2. By Vaccines
4.3. By Hormones
4.4. By Recombinant Proteins
4.5. By Other Applications
5. Asia Pacific Next-gen Biomanufacturing Market - by End User
5.1. By Biopharmaceutical Companies
5.2. By Research Institutions
5.3. By CMOs/CDMOs
Chapter 7 Latin America Next-gen Biomanufacturing Market - Segment Analysis
1. Overview
2. Latin America Next-gen Biomanufacturing Market, 2021 - 2035 (USD Million)
3. Latin America Next-gen Biomanufacturing Market - by Workflow Type
3.1. By Continuous Upstream Biomanufacturing Workflow
3.2. By Single-Use Upstream Biomanufacturing Workflow
3.3. By Downstream Biomanufacturing Workflow
4. Latin America Next-gen Biomanufacturing Market - by Application
4.1. By Monoclonal Antibodies
4.2. By Vaccines
4.3. By Hormones
4.4. By Recombinant Proteins
4.5. By Other Applications
5. Latin America Next-gen Biomanufacturing Market - by End User
5.1. By Biopharmaceutical Companies
5.2. By Research Institutions
5.3. By CMOs/CDMOs
Chapter 8 Middle East & Africa Next-gen Biomanufacturing Market - Segment Analysis
1. Overview
2. Middle East & Africa Next-gen Biomanufacturing Market, 2021 - 2035 (USD Million)
3. Middle East & Africa Next-gen Biomanufacturing Market - by Workflow Type
3.1. By Continuous Upstream Biomanufacturing Workflow
3.2. By Single-Use Upstream Biomanufacturing Workflow
3.3. By Downstream Biomanufacturing Workflow
4. Middle East & Africa Next-gen Biomanufacturing Market - by Application
4.1. By Monoclonal Antibodies
4.2. By Vaccines
4.3. By Hormones
4.4. By Recombinant Proteins
4.5. By Other Applications
5. Middle East & Africa Next-gen Biomanufacturing Market - by End User
5.1. By Biopharmaceutical Companies
5.2. By Research Institutions
5.3. By CMOs/CDMOs
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Merck KGaA (Germany)
2. Danaher Corp. (U.S.)
3. Sartorius AG (Germany)
4. Applikon Biotechnology B.V. (Netherlands)
5. Getinge AB (Sweden)
6. Thermo Fisher Scientific Inc. (U.S.)
7. PBS Biotech Inc. (U.S.)
8. bbi-biotech GmbH (Germany)
9. Solaris Biotechnology (Italy)
10. Meissner Corp. (U.S.)
11. ESCO Group LLC (U.S.)
12. GEA Group (Germany)
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By